

**Anti-Complement component C2 (human)  
Mouse monoclonal antibody**

Subclass: IgG1/k

PRODUCT NO.

**HYB 050-08**

Clone: 6E3-(C2S11)

PRESENTATION

Preparation: Protein-A/G purified

Content: Available in 200 µL and 1 mL volumes, 1 mg/mL

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: In the dark at 4-8°C

ANTIGEN

Complement component C2 is a component of the classical complement pathway and is involved in activation of C3 and C5. C2 consists of a single polypeptide chain with a molecular mass of 102 kDa (2).

IMMUNOGEN

Complement component C2 isolated from human plasma adsorbed onto aluminum hydroxide gel(1)

SPECIFICITY

HYB 050-08 is specific for C2 from human plasma/serum. Cross-reactivity to C2 from other species has not been tested.

EPI TOPE SPECIFICITY

Epitope specificity differs from that of HYB 050-04 and HYB 050-05 as determined by inhibition ELISA.

REACTIVITY

HYB 050-08 reacts strongly with C2. A strong reaction is seen with human serum/plasma and no reaction is seen with serum from patients deficient in C2, when tested in sandwich ELISA with a polyclonal antibody against C2. In Western blotting after SDS-PAGE, HYB 050-08 reacts with C2 and a subfraction of C2 believed to be C2b, both under reducing and non-reducing conditions. In ELISA, reaction is also seen with C2 directly coated onto the microtiter well.

CULTURE MEDIUM

Dulbecco's modified Eagle's medium with 10% fetal calf serum

FUSION PARTNER

X63-Ag8.653

IMMUNIZATION

Female CF1 x BALB/c mice immunized by intraperitoneal injection

APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes	1/4000	1
Immunoblotting	Yes	1/250	1
Immunohistochemistry	Not determined		

The dilution guideline for ELISA is based on sandwich ELISA in combination with a polyclonal antibody against the antigen. Users should determine the optimal dilutions for their own purpose.

REFERENCES

1. Stenbaek EI, Koch C, Barkholt V, Welinder KG (1986) Human complement component C2: production and characterization of polyclonal and monoclonal antibodies against C2. Mol Immunol 23:879-886.
2. Law SKA, Reid KBM (1988) Complement. In: In Focus (Ed. Male D) IRL Press: Oxford.

**CONDITIONS**

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.